Compare RSKD & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSKD | IRWD |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.0M | 663.6M |
| IPO Year | 2021 | 2009 |
| Metric | RSKD | IRWD |
|---|---|---|
| Price | $5.11 | $4.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $5.96 | ★ $7.67 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $12.09 | $57.95 |
| Revenue Next Year | $10.08 | $4.39 |
| P/E Ratio | ★ N/A | $17.17 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $3.70 | $0.67 |
| 52 Week High | $5.68 | $5.78 |
| Indicator | RSKD | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 64.61 |
| Support Level | $4.73 | $3.08 |
| Resistance Level | N/A | $4.50 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 78.57 | 91.67 |
Riskified Ltd offers an AI-powered e-commerce risk intelligence platform that identifies the individual behind each online interaction for legitimacy, helping merchants (its customers) eliminate risk and uncertainty from their business. The company's core product, the Chargeback Guarantee, automatically approves or declines online orders with performance levels that vary in accordance with its merchants' priorities. Additionally, it offers other products that mitigate similar e-commerce risks for those same merchants, including Policy Protect, Dispute Resolve, and Account Secure. Geographically, Riskified generates maximum revenue from the United States, and the rest from other regions of the Americas, Europe, the Middle East and Africa (EMEA), and the Asia-Pacific (APAC) region.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.